966 research outputs found
Fecal S100A12 levels measured by a new ELISA are increased in ulcerative colitis (UC) and Crohnâs disease (CD) and correlates with intestinal damage
Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]
To determine the efficacy and safety of risedronate in patients with knee osteoarthritis (OA), the British study of risedronate in structure and symptoms of knee OA (BRISK), a 1-year prospective, double-blind, placebo-controlled study, enrolled patients (40â80 years of age) with mild to moderate OA of the medial compartment of the knee. The primary aims were to detect differences in symptoms and function. Patients were randomized to once-daily risedronate (5 mg or 15 mg) or placebo. Radiographs were taken at baseline and 1 year for assessment of joint-space width using a standardized radiographic method with fluoroscopic positioning of the joint. Pain, function, and stiffness were assessed using the Western Ontario and McMaster Universities (WOMAC) OA index. The patient global assessment and use of walking aids were measured and bone and cartilage markers were assessed. The intention-to-treat population consisted of 284 patients. Those receiving risedronate at 15 mg showed improvement of the WOMAC index, particularly of physical function, significant improvement of the patient global assessment (P < 0.001), and decreased use of walking aids relative to patients receiving the placebo (P = 0.009). A trend towards attenuation of joint-space narrowing was observed in the group receiving 15 mg risedronate. Eight percent (n = 7) of patients receiving placebo and 4% (n = 4) of patients receiving 5 mg risedronate exhibited detectable progression of disease (joint-space width â„ 25% or â„ 0.75 mm) versus 1% (n = 1) of patients receiving 15 mg risedronate (P = 0.067). Risedronate (15 mg) significantly reduced markers of cartilage degradation and bone resorption. Both doses of risedronate were well tolerated. In this study, clear trends towards improvement were observed in both joint structure and symptoms in patients with primary knee OA treated with risedronate
Markers of bone turnover for the management of patients with bone metastases from prostate cancer
Although increased bone formation is a prominent feature of patients with osteosclerotic metastases from prostate cancer, there is also some evidence for increased bone resorption. The aim of this study was to compare the clinical utility of new bone resorption markers to that of bone formation in patients with bone metastases from prostate cancer before and after bisphosphonate treatment. Thirty-nine patients with prostate cancer and bone metastasis, nine patients with prostate cancer without bone metastases, nine patients with benign prostatic hyperplasia and 355 healthy age-matched men were included. Urinary non-isomerized (α CTX) and ÎČ isomerized (ÎČ CTX) type I collagen C-telopeptides (CTX) and a new assay for serum CTX were used to assess bone resorption. Bone formation was determined by serum osteocalcin, serum total (T-ALP) and bone (BAP) alkaline phosphatase and serum type I collagen C-terminal propeptide (PICP). Fourteen patients with bone metastases were also evaluated 15 days after a single injection of the bisphosphonate pamidronate (120 mg). Levels of all bone formation and bone resorption markers were significantly (P< 0.006â0.0001) higher in patients with prostate cancer and bone metastasis than in patients with benign prostatic hyperplasia, patients with prostate cancer without bone metastases and healthy controls. In patients with bone metastases the median was increased by 67% for serum osteocalcin, 128% for T-ALP, 138% for BAP, 79% for PICP, 220% for urinary α CTX, 149% for urinary ÎČ CTX and 214% for serum CTX. After bisphosphonate treatment all three resorption markers significantly decreased by an average of 65% (P = 0.001), 71% (P = 0.0010) and 61% (P = 0.0015) for urinary α CTX, urinary ÎČ CTX and serum CTX, respectively, whereas no significant change was observed for any bone formation markers. Patients with prostate cancer and bone metastases exhibit a marked increase in bone resorption, which decreases within a few days of treatment with pamidronate. These findings suggest that these new resorption markers may be useful for the management of these patients. © 2000 Cancer Research Campaig
P106 BIOMARKERS DEMONSTRATE DEGRADATION AND INFLAMMATION AS CHARACTERISTICS OF IDIOPATHIC OSTEOARTHRITIS (OA)
66 A NEW SERUM-BASED ASSAY FOR TYPE II COLLAGEN HELICAL PEPTIDE (SERUM HELIX-II) IS ASSOCIATED WITH LONG-TERM RADIOLOGICAL PROGRESSION IN KNEE OSTEOARTHRITIS
Parùmetros genéticos estimados por anålise bayesiana para peso e escore de precocidade ao sobreano de bovinos brangus.
ZOOTEC 2009
Improving the WALKABILITY for Next-Generation Cities and Territories, through the Reuse of Available Data ad Raster Analysis
Clusters of biochemical markers are associated with radiographic subtypes of osteoarthritis (OA) in subject with familial OA at multiple sites. The GARP study
SummaryObjectiveTo assess the relationship of biochemical markers and radiographic signs of osteoarthritis (ROA) in the subjects with symptomatic osteoarthritis (OA) at multiple sites of the Genetics osteoARthritis and Progression (GARP) study.MethodsWe have measured eight biochemical markers, representing tissue turnover of cartilage, bone, synovium, and inflammation. ROA was assessed in the knees, hips, hands, vertebral facet joints and spinal disc degeneration (DD) by using the Kellgren score. A proportionate score was subsequently made for each joint location based on the number of joints with ROA. Principal component and linear mixed model analyses were applied to analyze the data.ResultsThree different clusters of markers were identified that may reflect different pathophysiological processes of OA. The first component appeared to be reflected by structural markers of cartilage and bone turnover and associated especially in subjects with hip ROA. The second component was reflected by a marker of inflammation and was associated with knee ROA, high Western Ontario and McMaster Universities (WOMAC) scores and body mass index (BMI). The third component included markers of cartilage turnover and was associated with ROA at hands, spine as well as age. High familial aggregation was observed for serum cartilage oligomeric matrix protein (S-COMP) (70%) and serum N-propeptide of collagen type IIA (S-PIIANP) (62%).ConclusionUsing a large well-characterized study and eight biochemical markers, we were able to observe three components that may reflect different molecular mechanisms (bone, cartilage, synovium turnover and inflammation). Our data suggested that these components contribute differently to ROA at different joint sites
Tomographic imaging by coding and reconstruction
We present the various researches we made on tomographic imaging by coding and reconstruction . These works are based on
two chief kinds of methods : Coding Aperture Imaging and Transaxial Tomography, each of them including theoretical studies
and realization of tomographic systems for definite applications .
In this paper, we mainly present the more recent studies concerning reconstruction problems from missing data, with development
of an original method by "constrained natural pixels", and implementation of multislit coding in micro-imaging of laser plasmas .Nous présentons les divers travaux que nous avons réalisés sur l'imagerie tomographique par codage et reconstruction . Ces
travaux sont axés sur deux grands types de méthodes : l'Imagerie par Ouverture de Codage et la Tomographie Axiale
Transverse, et comprennent, pour chacune d'elles, des études théoriques et la conception de systÚmes tomographiques pour
des applications bien précises .
Dans cet article, nous présentons essentiellement les études les plus récentes qui concernent les problÚmes de reconstruction
à données incomplÚtes, avec le développement d'une méthode originale par «pixels naturels avec contrainte», et la mise en
ceuvre d'un codage par multifentes en micro-imagerie de plasmas laser
- âŠ